DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025

Core Points - Diagnos Inc. intends to extend the exercise period of 3,502,931 stock warrants to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants remains unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos Inc. is a Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [4] - The company aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]